Literature DB >> 29467349

Targeting of severe fever with thrombocytopenia syndrome virus structural proteins to the ERGIC (endoplasmic reticulum Golgi intermediate compartment) and Golgi complex.

Tapiwa Lundu1,2, Yoshimi Tsuda3, Ryo Ito3, Kenta Shimizu3, Shintaro Kobayashi4, Kentaro Yoshii4, Kumiko Yoshimatsu3, Jiro Arikawa3, Hiroaki Kariwa4.   

Abstract

Severe fever with thrombocytopenia syndrome phlebovirus (SFTSV) is a newly emerged phlebovirus identified in China, Japan, and South Korea. Phlebovirus glycoproteins (GP) play a key role in targeting viral structural components to the budding compartments in the ER-Golgi intermediate compartment (ERGIC) and Golgi complex. However, the role of SFTSV GP in targeting structural proteins to the ERGIC and Golgi complex remains unresolved. In this study, we show that SFTSV GP plays a significant role in targeting RNA-dependent RNA polymerase (L) and nucleocapsid protein (NP) to the budding sites. Confocal microscopy was used to investigate the subcellular localization of SFTSV structural proteins. In SFTSV-infected cells, GP and L localized to the ER, ERGIC and Golgi complex, whereas NP localized to the ERGIC and Golgi complex. In addition, GP colocalized with L and NP in infected cells. In cells singly transfected with GP, L or NP, GP localized to the same subcellular compartments as in infected cells. However, L or NP alone did not localize to the ER, ERGIC, or Golgi complex. Cotransfection experiments showed that GP altered the localization of L to the ERGIC and Golgi complex but not that of NP. Interestingly, plasmid-expressed NP fused with a hemagglutinin tag localized to the ERGIC and Golgi complex when expressed in SFTSV-infected cells and colocalised with GP, suggesting that GP plays a role in the subcellular localization of L and NP in infected cells. Thus, the SFTSV structural components start to assemble at the ERGIC to Golgi complex. GP is required for transporting L and NP to the ERGIC and Golgi complex. In addition, targeting of NP requires interaction with other factors besides GP.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29467349     DOI: 10.2220/biomedres.39.27

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  5 in total

1.  Bunyavirus SFTSV exploits autophagic flux for viral assembly and egress.

Authors:  Jia-Min Yan; Wen-Kang Zhang; Li-Na Yan; Yong-Jun Jiao; Chuan-Min Zhou; Xue-Jie Yu
Journal:  Autophagy       Date:  2021-11-06       Impact factor: 13.391

2.  Quantitative Proteomic Analysis Reveals Unfolded-Protein Response Involved in Severe Fever with Thrombocytopenia Syndrome Virus Infection.

Authors:  Lei-Ke Zhang; Bo Wang; Qilin Xin; Weijuan Shang; Shu Shen; Gengfu Xiao; Fei Deng; Hualin Wang; Zhihong Hu; Manli Wang
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

Review 3.  Golgi Structure and Function in Health, Stress, and Diseases.

Authors:  Jie Li; Erpan Ahat; Yanzhuang Wang
Journal:  Results Probl Cell Differ       Date:  2019

4.  Subcellular localization of nucleocapsid protein of SFTSV and its assembly into the ribonucleoprotein complex with L protein and viral RNA.

Authors:  Sithumini M W Lokupathirage; Yoshimi Tsuda; Kodai Ikegame; Kisho Noda; Devinda S Muthusinghe; Fumiya Kozawa; Rashid Manzoor; Kenta Shimizu; Kumiko Yoshimatsu
Journal:  Sci Rep       Date:  2021-11-26       Impact factor: 4.379

5.  A Model for the Production of Regulatory Grade Viral Hemorrhagic Fever Exposure Stocks: From Field Surveillance to Advanced Characterization of SFTSV.

Authors:  Unai Perez-Sautu; Se Hun Gu; Katie Caviness; Dong Hyun Song; Yu-Jin Kim; Nicholas Di Paola; Daesang Lee; Terry A Klein; Joseph A Chitty; Elyse Nagle; Heung-Chul Kim; Sung-Tae Chong; Brett Beitzel; Daniel S Reyes; Courtney Finch; Russ Byrum; Kurt Cooper; Janie Liang; Jens H Kuhn; Xiankun Zeng; Kathleen A Kuehl; Kayla M Coffin; Jun Liu; Hong Sang Oh; Woong Seog; Byung-Sub Choi; Mariano Sanchez-Lockhart; Gustavo Palacios; Seong Tae Jeong
Journal:  Viruses       Date:  2020-08-29       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.